A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Vilazodone (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan; Forest Laboratories
- 09 Apr 2018 Results assessing efficacy, safety, and tolerability published in the Pediatric Drugs
- 06 Oct 2016 Status changed from active, no longer recruiting to completed.
- 15 Jun 2016 Status changed from recruiting to active, no longer recruiting.